Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
- Conditions
- Peripheral Neuropathy Due to Chemotherapy
- Registration Number
- NCT06135493
- Lead Sponsor
- Future University in Egypt
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br> - Females older than 18 years diagnosed with biopsy-confirmed breast cancer (Early<br> breast cancer eligible for adjuvant or neoadjuvant) who are scheduled to receive<br> paclitaxel 80 mg/m2.<br><br>Exclusion Criteria:<br><br> - Known hypersensitivity to Losartan.<br><br> - Not Known Hypertensive patients<br><br> - Not Known Diabetic patients<br><br> - Treatment with Losartan/ARBs/ACE-I prior to the study.<br><br> - Previous neuropathy<br><br> - Renal impairment (Serum creatinine > 2 mg/dl)<br><br> - Significant liver disease: liver enzymes 2 folds the upper normal limit<br><br> - Metastatic breast cancer<br><br> - Pregnancy or lactation<br><br> - Taking other medication for neuropathic pain<br><br> - Significant Hypotension
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Development of paclitaxel-induced peripheral neuropathy;Grade of neuropathy
- Secondary Outcome Measures
Name Time Method Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX);Biomarker